Hints and tips:
Related Special Reports
...Sandoz forecast net sales growth in the mid-single digits for 2023 and in the medium term, as it expected a return to growth in the US and launches of biosimilars including a version of the blockbuster anti-inflammatory...
...The Swiss group is a cleaner proposition after spinning off its generics business Sandoz in October. But there is no time to stand still. Narasimhan must show that Novartis can increase revenues....
...In 2022, Accord provided 35 per cent of the US’s methotrexate supply as well as more than half of the US supply of other key cancer drugs: carboplatin and cisplatin....
...The results focus on the remaining business, focused on innovative drugs, after Novartis spun out its generics division Sandoz this month....
...The Citrix deal, along with the $5.4bn financing package for Apollo’s takeover of automotive supplier Tenneco, have both been postponed this month until after the US Labor Day holiday in September....
...US-Taiwan: The presidential candidate of Taiwan’s largest opposition party plans to push the White House to clarify its commitment to defending his country when he visits the US over the coming week. 3....
...Adobe Q3, IG Group Q1 trading update, John Lewis Partnership H1, Kier Group FY, M&C Saatchi H1, THG H1, Trainline H1 trading update Friday Novartis holds extraordinary shareholders meeting to vote on Sandoz...
...Novartis had already attempted to shed parts of Sandoz to India’s Aurobindo in 2020, but competition concerns from US regulators scuppered the nearly $1bn deal in 2020....
...Novartis recently said it would spin off its generic drugmaking business Sandoz....
...She’s explained to us the stratagem for enlarging our presence abroad including hosting press lunches for us at Carnegie Hall....
...Sandoz’s advantage is that only a fifth of sales are in the ultra-competitive US market....
...Sandoz, one of the largest generic antibiotics makers, said it had increased production of drugs by a double-digit percentage in 2022, hiring 140 new people since September....
...We’d also like to commend the reader below for leaving us with this witty comment....
...The drugmaker attempted to offload parts of the US Sandoz business in 2018 to Aurobindo, though the transaction was eventually called off last year because the deal did not receive approval from the US Federal...
...Competition is intense, particularly in the US. The generics division has long weighed on profitability....
...“It seems the sense of urgency from clients [to hedge] has been pretty light,” Barclays’ Sandoz added....
...Novartis had sought to offload parts of the US unit of Sandoz in 2018 but regulators scuppered the transaction....
...In the US Victor Bulto, head of US pharmaceuticals, will become president of the US division of innovative medicines....
...News round-up Capital Group: the slow-moving giant in dangerous waters (FT) Novartis to spin off generic drugs unit Sandoz (FT) CIMC abandons $1bn deal for Maersk’s refrigerated container arm (FT) Citigroup...
...Psilocybin was first clinically manufactured in 1959 by Sandoz, now part of Novartis, but the company had never commercialised it....
...National health services and drugmakers including GSK, Novartis’ Sandoz, and Bayer have been sending antibiotics to stop sepsis and other diseases caused by bacteria....
...Sandoz, a subsidiary of Swiss pharma giant Novartis, said it was a small player in the dexamethasone market, but was evaluating the situation....
...“We were not expecting it, it came to us as a surprise.”...
...One thing to watch: Several private equity firms including Blackstone, Carlyle and EQT are considering bids of up to $25bn for Sandoz, the generic drugs business belonging to pharmaceutical company Novartis...
...(Forbes) News round-up Vodafone chief says turnround push happening despite activist (FT + Lex) Novartis says all options open on Sandoz after private equity interest emerges (FT + Lex) First black woman...
International Edition